Dr. Ping Chi, M.D., PH.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 58
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 234703
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 58
- Services billed
- 216
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 150 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 44 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 14 | 11 |
| Hospital discharge day management, more than 30 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 234 |
| Gleevec (imatinib mesylate) | 32 |
| Ondansetron Hcl Other prescribers in New York, NY | 13 |
| Oxycodone Hcl Other prescribers in New York, NY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $3,402 in total to this clinician.
| Deciphera Pharmaceuticals Inc. | $3,329 |
|---|---|
| GlaxoSmithKline, LLC. | $49.99 |
| Biomerieux Inc | $23.00 |
| Honoraria | $2,340 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $585 |
| Food and Beverage | $198 |
| Travel and Lodging | $183 |
| Gift | $95.53 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Jan 17, 2025 | Honoraria QINLOCK · ONCOLOGY | $2,340 |
| Deciphera Pharmaceuticals Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $585 |
| Deciphera Pharmaceuticals Inc. Jan 17, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to BOCA RATON, FL · in-kind | $183 |
| Deciphera Pharmaceuticals Inc. Nov 14, 2025 | Gift ROMVIMZA · ONCOLOGY · in-kind | $49.38 |
| Deciphera Pharmaceuticals Inc. Jun 4, 2025 | Gift QINLOCK · ONCOLOGY · in-kind | $46.15 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $2,015,714 in research payments for these studies, mostly to the institutions running them.
- A master protocol for the multi-cohort, phase 1/2 study of DCC-3116 in combination with anticancer therapies in participants with advanced malignancies
Deciphera Pharmaceuticals Inc. - A master protocol to evaluate DCC-3009 in gastrointestinal stromal tumor (gist)
Deciphera Pharmaceuticals Inc. - A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Deciphera Pharmaceuticals Inc. · Active, not recruiting · NCT05734105 - A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Deciphera Pharmaceuticals Inc. · Active, not recruiting · NCT03673501
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.